Who are ceftriaxone sodium + metronidazole's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Antibiotics, cefuroxime and metronidazole, Amoxicillin, Metronidazole.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ceftriaxone-sodium-metronidazole.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

ceftriaxone sodium + metronidazole — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ceftriaxone sodium + metronidazole (ceftriaxone sodium + metronidazole) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-lactam antibiotic + nitroimidazole antibiotic combination. Area: Infectious Disease.

marketed Beta-lactam antibiotic + nitroimidazole antibiotic combination Bacterial penicillin-binding proteins (ceftriaxone); anaerobic bacterial DNA (metronidazole) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

ceftriaxone sodium + metronidazole (ceftriaxone sodium + metronidazole) — Wyeth is now a wholly owned subsidiary of Pfizer. This combination uses a third-generation cephalosporin to inhibit bacterial cell wall synthesis and a nitroimidazole to disrupt anaerobic bacterial DNA, providing broad-spectrum coverage against aerobic gram-negative, gram-positive, and anaerobic organisms.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ceftriaxone sodium + metronidazole TARGET	ceftriaxone sodium + metronidazole	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Beta-lactam antibiotic + nitroimidazole antibiotic combination	Bacterial penicillin-binding proteins (ceftriaxone); anaerobic bacterial DNA (metronidazole)
Antibiotics, cefuroxime and metronidazole	Antibiotics, cefuroxime and metronidazole	Helsinki University Central Hospital	marketed	Beta-lactam antibiotic + nitroimidazole antibiotic combination	Bacterial penicillin-binding proteins (cefuroxime); anaerobic bacterial DNA (metronidazole)
Amoxicillin, Metronidazole	Amoxicillin, Metronidazole	Shanghai Jiao Tong University School of Medicine	marketed	Beta-lactam antibiotic + nitroimidazole antibiotic combination	Penicillin-binding proteins (amoxicillin); anaerobic DNA (metronidazole)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-lactam antibiotic + nitroimidazole antibiotic combination class)

Helsinki University Central Hospital · 1 drug in this class
Shanghai Jiao Tong University School of Medicine · 1 drug in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ceftriaxone sodium + metronidazole — Competitive Intelligence Brief. https://druglandscape.com/ci/ceftriaxone-sodium-metronidazole. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab